Please note that the ANZCTR website will be unavailable from 1pm until 2pm (AEST) on Wednesday 29th May for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00917384




Registration number
NCT00917384
Ethics application status
Date submitted
8/06/2009
Date registered
9/06/2009
Date last updated
8/12/2016

Titles & IDs
Public title
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
Scientific title
A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy
Secondary ID [1] 0 0
2008-005964-15
Secondary ID [2] 0 0
13893
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gastric Cancer 0 0
Adenocarcinoma 0 0
Gastric Cancer 0 0
Adenocarcinoma 0 0
Gastric Cancer 0 0
Adenocarcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Stomach
Cancer 0 0 0 0
Oesophageal (gullet)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - ramucirumab
Treatment: Drugs - Placebo
Other interventions - Best Supportive Care (BSC)
Other interventions - ramucirumab
Treatment: Drugs - Placebo
Other interventions - Best Supportive Care (BSC)
Other interventions - ramucirumab
Treatment: Drugs - Placebo
Other interventions - Best Supportive Care (BSC)

Experimental: ramucirumab - Participants receive ramucirumab, administered via intravenous infusion every 2 weeks at a dose of 8 milligrams/kilogram (mg/kg), and best supportive care (BSC) as determined appropriate by the investigator(s). Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.

Placebo Comparator: Placebo - Participants receive injection for intravenous infusion every 2 weeks plus BSC as determined appropriate by the investigator(s). Because investigators and ancillary medical personnel will be blinded as to assignment to active therapy versus placebo, the volume of placebo to be administered will be calculated as if it were active product with a dose of 8 mg/kg. Treatment will continue until there is evidence of PD, the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.

Experimental: ramucirumab - Participants receive ramucirumab, administered via intravenous infusion every 2 weeks at a dose of 8 milligrams/kilogram (mg/kg), and best supportive care (BSC) as determined appropriate by the investigator(s). Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.

Placebo Comparator: Placebo - Participants receive injection for intravenous infusion every 2 weeks plus BSC as determined appropriate by the investigator(s). Because investigators and ancillary medical personnel will be blinded as to assignment to active therapy versus placebo, the volume of placebo to be administered will be calculated as if it were active product with a dose of 8 mg/kg. Treatment will continue until there is evidence of PD, the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.

Experimental: ramucirumab - Participants receive ramucirumab, administered via intravenous infusion every 2 weeks at a dose of 8 milligrams/kilogram (mg/kg), and best supportive care (BSC) as determined appropriate by the investigator(s). Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.

Placebo Comparator: Placebo - Participants receive injection for intravenous infusion every 2 weeks plus BSC as determined appropriate by the investigator(s). Because investigators and ancillary medical personnel will be blinded as to assignment to active therapy versus placebo, the volume of placebo to be administered will be calculated as if it were active product with a dose of 8 mg/kg. Treatment will continue until there is evidence of PD, the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.


Other interventions: ramucirumab
Administered via intravenous infusion every 2 weeks at a dose of 8 mg/kg

Treatment: Drugs: Placebo
Placebo comparator for ramucirumab 8 mg/kg as intravenous infusion every 2 weeks

Other interventions: Best Supportive Care (BSC)
BSC as determined appropriate by the investigator(s). BSC may include but are not limited to antiemetic agents, opiate and nonopiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.

Other interventions: ramucirumab
Administered via intravenous infusion every 2 weeks at a dose of 8 mg/kg

Treatment: Drugs: Placebo
Placebo comparator for ramucirumab 8 mg/kg as intravenous infusion every 2 weeks

Other interventions: Best Supportive Care (BSC)
BSC as determined appropriate by the investigator(s). BSC may include but are not limited to antiemetic agents, opiate and nonopiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.

Other interventions: ramucirumab
Administered via intravenous infusion every 2 weeks at a dose of 8 mg/kg

Treatment: Drugs: Placebo
Placebo comparator for ramucirumab 8 mg/kg as intravenous infusion every 2 weeks

Other interventions: Best Supportive Care (BSC)
BSC as determined appropriate by the investigator(s). BSC may include but are not limited to antiemetic agents, opiate and nonopiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.

Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival (OS) - Overall survival is defined as the time from the date of randomization to the date of death from any cause. Participants who were alive at the date of data cut-off or who were lost to follow-up were censored on the last date the participant was known to be alive
Timepoint [1] 0 0
Randomization up to 28 months post-randomization
Primary outcome [2] 0 0
Overall Survival (OS) - Overall survival is defined as the time from the date of randomization to the date of death from any cause. Participants who were alive at the date of data cut-off or who were lost to follow-up were censored on the last date the participant was known to be alive
Timepoint [2] 0 0
Randomization up to 28 months post-randomization
Primary outcome [3] 0 0
Overall Survival (OS) - Overall survival is defined as the time from the date of randomization to the date of death from any cause. Participants who were alive at the date of data cut-off or who were lost to follow-up were censored on the last date the participant was known to be alive
Timepoint [3] 0 0
Randomization up to 28 months post-randomization
Secondary outcome [1] 0 0
Progression-Free Survival (PFS) - PFS is defined as the time from date of randomization until date of objectively determined progressive disease (PD) or death due to any cause, whichever is first. Participants alive and without PD were censored at the time of last adequate objective tumor assessment (that is, response other than unevaluable).
Timepoint [1] 0 0
Randomization up to 17 months
Secondary outcome [2] 0 0
Percentage of Participants Who Are Progression-Free at Week 12 (PFS Rate) - The percentage of participants alive and progression-free 12 weeks after randomization. Progression-free survival (PFS) is defined as the time from the date of randomization until the date of objectively determined progressive disease (PD) or death due to any cause whichever comes first. Participants alive and without PD were censored at the time of the last adequate objective tumor assessment.
Timepoint [2] 0 0
Week 12 post-randomization
Secondary outcome [3] 0 0
Percentage of Participants With Objective Response (Objective Response Rate [ORR]) - ORR is equal to the percentage of participants achieving a best overall response of complete response (CR) or partial response (PR). CR and PR were defined using the Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR is defined as the disappearance of all target and non-target lesions, no appearance of new lesions and confirmed at the consecutive tumor assessment. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, no appearance of new lesions and confirmed at a subsequent tumor assessment.
Timepoint [3] 0 0
Randomization up to 17 months post-randomization
Secondary outcome [4] 0 0
Duration of Response (DOR) - DOR is the interval from date of initial documented response (complete response [CR] or partial response [PR]) to first documented date of disease progression (PD) or death as a result of any cause. CR and PR were defined using the Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR is defined as the disappearance of all target and non-target lesions, no appearance of new lesions and confirmed at the consecutive tumor assessment. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, no appearance of new lesions and confirmed at a subsequent tumor assessment. Participants who did not relapse or die were censored at the time of the last adequate objective tumor assessment.
Timepoint [4] 0 0
Randomization up to 17 months post-randomization
Secondary outcome [5] 0 0
Change From Baseline in Quality of Life (QoL) as Measured by the European Organisation for Research and Treatment of Cancer Questionnaire (EORTC-QLQ-C30) - EORTC QLQ-C30 v3.0 is a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, cognitive, emotional, and social), global health status, and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms. Best change from baseline results determined by Least Square (LS) mean estimated with randomization stratification factors and baseline value as continuous covariate.
Timepoint [5] 0 0
Baseline up to Cycle 10 (18 weeks [1 cycle=2 weeks])
Secondary outcome [6] 0 0
Number of Participants With Adverse Events - Clinically significant events were defined as serious adverse events (SAE) and other treatment-emergent non-serious adverse events (NSAE). A summary of SAEs and all other NSAEs is located in the Reported Adverse Event module.
Timepoint [6] 0 0
Randomization up to 18 months
Secondary outcome [7] 0 0
Maximum Concentration (Cmax) of IMC-1121B - Cmax was not analyzed as only pre-dose samples were collected.
Timepoint [7] 0 0
6 weeks post-randomization
Secondary outcome [8] 0 0
Number of Participants Who Developed Antibodies Against IMC-1121B - The number of participants who developed treatment emergent antibody responses to IMC-1121B after baseline.
Timepoint [8] 0 0
Baseline, 12 Weeks
Secondary outcome [9] 0 0
Progression-Free Survival (PFS) - PFS is defined as the time from date of randomization until date of objectively determined progressive disease (PD) or death due to any cause, whichever is first. Participants alive and without PD were censored at the time of last adequate objective tumor assessment (that is, response other than unevaluable).
Timepoint [9] 0 0
Randomization up to 17 months
Secondary outcome [10] 0 0
Percentage of Participants Who Are Progression-Free at Week 12 (PFS Rate) - The percentage of participants alive and progression-free 12 weeks after randomization. Progression-free survival (PFS) is defined as the time from the date of randomization until the date of objectively determined progressive disease (PD) or death due to any cause whichever comes first. Participants alive and without PD were censored at the time of the last adequate objective tumor assessment.
Timepoint [10] 0 0
Week 12 post-randomization
Secondary outcome [11] 0 0
Percentage of Participants With Objective Response (Objective Response Rate [ORR]) - ORR is equal to the percentage of participants achieving a best overall response of complete response (CR) or partial response (PR). CR and PR were defined using the Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR is defined as the disappearance of all target and non-target lesions, no appearance of new lesions and confirmed at the consecutive tumor assessment. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, no appearance of new lesions and confirmed at a subsequent tumor assessment.
Timepoint [11] 0 0
Randomization up to 17 months post-randomization
Secondary outcome [12] 0 0
Duration of Response (DOR) - DOR is the interval from date of initial documented response (complete response [CR] or partial response [PR]) to first documented date of disease progression (PD) or death as a result of any cause. CR and PR were defined using the Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR is defined as the disappearance of all target and non-target lesions, no appearance of new lesions and confirmed at the consecutive tumor assessment. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, no appearance of new lesions and confirmed at a subsequent tumor assessment. Participants who did not relapse or die were censored at the time of the last adequate objective tumor assessment.
Timepoint [12] 0 0
Randomization up to 17 months post-randomization
Secondary outcome [13] 0 0
Change From Baseline in Quality of Life (QoL) as Measured by the European Organisation for Research and Treatment of Cancer Questionnaire (EORTC-QLQ-C30) - EORTC QLQ-C30 v3.0 is a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, cognitive, emotional, and social), global health status, and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms. Best change from baseline results determined by Least Square (LS) mean estimated with randomization stratification factors and baseline value as continuous covariate.
Timepoint [13] 0 0
Baseline up to Cycle 10 (18 weeks [1 cycle=2 weeks])
Secondary outcome [14] 0 0
Number of Participants With Adverse Events - Clinically significant events were defined as serious adverse events (SAE) and other treatment-emergent non-serious adverse events (NSAE). A summary of SAEs and all other NSAEs is located in the Reported Adverse Event module.
Timepoint [14] 0 0
Randomization up to 18 months
Secondary outcome [15] 0 0
Maximum Concentration (Cmax) of IMC-1121B - Cmax was not analyzed as only pre-dose samples were collected.
Timepoint [15] 0 0
6 weeks post-randomization
Secondary outcome [16] 0 0
Number of Participants Who Developed Antibodies Against IMC-1121B - The number of participants who developed treatment emergent antibody responses to IMC-1121B after baseline.
Timepoint [16] 0 0
Baseline, 12 Weeks
Secondary outcome [17] 0 0
Progression-Free Survival (PFS) - PFS is defined as the time from date of randomization until date of objectively determined progressive disease (PD) or death due to any cause, whichever is first. Participants alive and without PD were censored at the time of last adequate objective tumor assessment (that is, response other than unevaluable).
Timepoint [17] 0 0
Randomization up to 17 months
Secondary outcome [18] 0 0
Percentage of Participants Who Are Progression-Free at Week 12 (PFS Rate) - The percentage of participants alive and progression-free 12 weeks after randomization. Progression-free survival (PFS) is defined as the time from the date of randomization until the date of objectively determined progressive disease (PD) or death due to any cause whichever comes first. Participants alive and without PD were censored at the time of the last adequate objective tumor assessment.
Timepoint [18] 0 0
Week 12 post-randomization
Secondary outcome [19] 0 0
Percentage of Participants With Objective Response (Objective Response Rate [ORR]) - ORR is equal to the percentage of participants achieving a best overall response of complete response (CR) or partial response (PR). CR and PR were defined using the Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR is defined as the disappearance of all target and non-target lesions, no appearance of new lesions and confirmed at the consecutive tumor assessment. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, no appearance of new lesions and confirmed at a subsequent tumor assessment.
Timepoint [19] 0 0
Randomization up to 17 months post-randomization
Secondary outcome [20] 0 0
Duration of Response (DOR) - DOR is the interval from date of initial documented response (complete response [CR] or partial response [PR]) to first documented date of disease progression (PD) or death as a result of any cause. CR and PR were defined using the Response Evaluation Criteria in Solid Tumors (RECIST v1.0). CR is defined as the disappearance of all target and non-target lesions, no appearance of new lesions and confirmed at the consecutive tumor assessment. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, no appearance of new lesions and confirmed at a subsequent tumor assessment. Participants who did not relapse or die were censored at the time of the last adequate objective tumor assessment.
Timepoint [20] 0 0
Randomization up to 17 months post-randomization
Secondary outcome [21] 0 0
Change From Baseline in Quality of Life (QoL) as Measured by the European Organisation for Research and Treatment of Cancer Questionnaire (EORTC-QLQ-C30) - EORTC QLQ-C30 v3.0 is a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, cognitive, emotional, and social), global health status, and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms. Best change from baseline results determined by Least Square (LS) mean estimated with randomization stratification factors and baseline value as continuous covariate.
Timepoint [21] 0 0
Baseline up to Cycle 10 (18 weeks [1 cycle=2 weeks])
Secondary outcome [22] 0 0
Number of Participants With Adverse Events - Clinically significant events were defined as serious adverse events (SAE) and other treatment-emergent non-serious adverse events (NSAE). A summary of SAEs and all other NSAEs is located in the Reported Adverse Event module.
Timepoint [22] 0 0
Randomization up to 18 months
Secondary outcome [23] 0 0
Maximum Concentration (Cmax) of IMC-1121B - Cmax was not analyzed as only pre-dose samples were collected.
Timepoint [23] 0 0
6 weeks post-randomization
Secondary outcome [24] 0 0
Number of Participants Who Developed Antibodies Against IMC-1121B - The number of participants who developed treatment emergent antibody responses to IMC-1121B after baseline.
Timepoint [24] 0 0
Baseline, 12 Weeks

Eligibility
Key inclusion criteria
- Histologically or cytologically confirmed gastric carcinoma, including gastric
adenocarcinoma or GEJ adenocarcinoma

- Metastatic disease or locally recurrent, unresectable disease with measurable lymph
node metastases

- Measurable disease and/or evaluable disease. Measurable disease is defined as at least
one unidimensionally-measurable target lesion [= 2 centimeter (cm) with conventional
techniques or = 1 cm by spiral computed tomography (CT)], as defined by Response using
Response Evaluation Criteria in Solid Tumors (RECIST).

Examples of evaluable, nonmeasurable disease include gastric, peritoneal, or mesenteric
thickening in areas of known disease, or peritoneal nodules that are too small to be
considered measurable by RECIST

- Experienced disease progression during or within 4 months after the last dose of
first-line therapy for metastatic disease, or during or within 6 months after the last
dose of adjuvant therapy

- Disease is not amenable to potentially curative resection

- Participant is = 18 years of age

- Participant has a life expectancy of = 12 weeks

- Participant resolution to Grade = 1 (or to Grade = 2 in the case of neuropathy) by the
National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE),
Version 3.0, of all clinically significant toxic effects of prior chemotherapy,
surgery, radiotherapy, or hormonal therapy (with the exception of alopecia)

- Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0-1

- The participant has adequate hepatic function as defined by a total bilirubin = 1.5
milligrams/deciliter (mg/dL) [25.65 micromole/liter (µmol/L)], and aspartate
transaminase (AST) and alanine transaminase (ALT) = 3.0 x the upper limit of normal
(ULN) [or 5.0 x the ULN in the setting of liver metastases]

- The participant has adequate renal function as defined by a serum creatinine = 1.5 x
the ULN, or creatinine clearance (measured via 24-hour urine collection) = 40
milliliters/minute (mL/min) (that is, if serum creatinine is > 1.5 x the ULN, a
24-hour urine collection to calculate creatinine clearance must be performed)

- The participant's urinary protein is = 1+ on dipstick or routine urinalysis ([UA]; if
urine dipstick or routine analysis is = 2+, a 24-hour urine collection for protein
must demonstrate < 1000 milligrams (mg) of protein in 24 hours to allow participation
in the study)

- The participant has adequate hematologic function, as evidenced by an absolute
neutrophil count (ANC) = 1000 microliters (µL), hemoglobin = 9 grams/deciliter (g/dL)
[5.58 millimoles/liter (mmol/L)], and platelets = 100,000/µL

- The participant must have adequate coagulation function as defined by International
Normalized Ratio (INR) = 1.5 and a partial thromboplastin time (PTT) = 5 seconds above
the ULN (unless receiving anticoagulation therapy). Participant on anticoagulation
therapy with unresected primary tumors or local tumor recurrence following resection
are not eligible

- If the participant has received prior anthracycline therapy as part of his or her
first-line regimen, the participant is able to engage in ordinary physical activity
without significant fatigue or dyspnea

- Because the teratogenicity of IMC-1121B is not known, the participant, if sexually
active, must be postmenopausal, surgically sterile, or using effective contraception
(hormonal or barrier methods)

- Female participant of childbearing potential must have a negative serum pregnancy test
within 7 days prior to randomization

- Able to provide informed written consent and is amenable to compliance with protocol
schedules and testing
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Documented and/or symptomatic brain or leptomeningeal metastases

- Experienced any Grade 3-4 gastrointestinal bleeding within 3 months prior to
randomization

- Experienced any arterial thromboembolic events, including but not limited to
myocardial infarction, transient ischemic attack, cerebrovascular accident, or
unstable angina, within 6 months prior to randomization

- Ongoing or active infection, symptomatic congestive heart failure, unstable angina
pectoris, symptomatic or poorly controlled cardiac arrhythmia, uncontrolled thrombotic
or hemorrhagic disorder, or any other serious uncontrolled medical disorders in the
opinion of the investigator

- Ongoing or active psychiatric illness or social situation that would limit compliance
with study requirements

- Uncontrolled or poorly-controlled hypertension despite standard medical management

- Participant has a serious or nonhealing wound, ulcer, or bone fracture

- Received chemotherapy, radiotherapy, immunotherapy, or targeted therapy for gastric
cancer within 2 weeks prior to randomization

- Received any investigational therapy within 30 days prior to randomization

- Undergone major surgery within 28 days prior to randomization, or subcutaneous venous
access device placement within 7 days prior to randomization

- Received prior therapy with an agent that directly inhibits vascular endothelial
growth factor (VEGF) or VEGF receptor 2 (R-2) activity (including bevacizumab), or any
antiangiogenic agent

- Receiving chronic antiplatelet therapy, including aspirin, nonsteroidal
anti-inflammatory drugs (NSAIDs, including ibuprofen, naproxen, and others),
dipyridamole or clopidogrel, or similar agents. Once-daily aspirin use [maximum dose
325 milligram/day (mg/day)] is permitted

- Participant has elective or planned major surgery to be performed during the course of
the clinical trial

- Participant has a known allergy to any of the treatment components

- Pregnant or lactating

- Known to be positive for infection with the human immunodeficiency virus

- Known alcohol or drug dependency

- Participant has a concurrent active malignancy other than adequately-treated
nonmelanomatous skin cancer, other noninvasive carcinoma, or in situ neoplasm. A
participant with previous history of malignancy is eligible, provided that he/she has
been free of disease for > 3 years

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,TAS,VIC,WA
Recruitment hospital [1] 0 0
ImClone Investigational Site - Wodonga
Recruitment hospital [2] 0 0
ImClone Investigational Site - Hobart
Recruitment hospital [3] 0 0
ImClone Investigational Site - East Melbourne
Recruitment hospital [4] 0 0
ImClone Investigational Site - Perth
Recruitment hospital [5] 0 0
ImClone Investigational Site - Bedford Park
Recruitment hospital [6] 0 0
ImClone Investigational Site - St. Leonards
Recruitment hospital [7] 0 0
ImClone Investigational Site - Woodville
Recruitment postcode(s) [1] 0 0
3690 - Wodonga
Recruitment postcode(s) [2] 0 0
7000 - Hobart
Recruitment postcode(s) [3] 0 0
3002 - East Melbourne
Recruitment postcode(s) [4] 0 0
6000 - Perth
Recruitment postcode(s) [5] 0 0
5042 - Bedford Park
Recruitment postcode(s) [6] 0 0
NSW 2065 - St. Leonards
Recruitment postcode(s) [7] 0 0
5011 - Woodville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Illinois
Country [3] 0 0
United States of America
State/province [3] 0 0
Louisiana
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
Nebraska
Country [6] 0 0
United States of America
State/province [6] 0 0
New York
Country [7] 0 0
United States of America
State/province [7] 0 0
Pennsylvania
Country [8] 0 0
United States of America
State/province [8] 0 0
Rhode Island
Country [9] 0 0
United States of America
State/province [9] 0 0
South Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Tennessee
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
Argentina
State/province [12] 0 0
Buenos Aires
Country [13] 0 0
Argentina
State/province [13] 0 0
Capital Federal
Country [14] 0 0
Argentina
State/province [14] 0 0
Ciudad Autonoma de Buenos Aires
Country [15] 0 0
Argentina
State/province [15] 0 0
Ciudada Autonoma
Country [16] 0 0
Argentina
State/province [16] 0 0
Cordoba
Country [17] 0 0
Argentina
State/province [17] 0 0
Rosario
Country [18] 0 0
Bosnia and Herzegovina
State/province [18] 0 0
Sarajevo
Country [19] 0 0
Brazil
State/province [19] 0 0
Barretos
Country [20] 0 0
Brazil
State/province [20] 0 0
Belo Horizonte
Country [21] 0 0
Brazil
State/province [21] 0 0
Brasilia
Country [22] 0 0
Brazil
State/province [22] 0 0
Curitiba
Country [23] 0 0
Brazil
State/province [23] 0 0
Florianopolis
Country [24] 0 0
Brazil
State/province [24] 0 0
Ijui
Country [25] 0 0
Brazil
State/province [25] 0 0
Lajeados
Country [26] 0 0
Brazil
State/province [26] 0 0
Londrina
Country [27] 0 0
Brazil
State/province [27] 0 0
Passo Fundo
Country [28] 0 0
Brazil
State/province [28] 0 0
Porto Alegre
Country [29] 0 0
Brazil
State/province [29] 0 0
Sao Paulo
Country [30] 0 0
Canada
State/province [30] 0 0
Alberta
Country [31] 0 0
Canada
State/province [31] 0 0
Quebec
Country [32] 0 0
Chile
State/province [32] 0 0
Concepcion
Country [33] 0 0
Chile
State/province [33] 0 0
La Serena
Country [34] 0 0
Chile
State/province [34] 0 0
Santiago
Country [35] 0 0
Colombia
State/province [35] 0 0
Monteria
Country [36] 0 0
Croatia
State/province [36] 0 0
Osijek
Country [37] 0 0
Croatia
State/province [37] 0 0
Pula
Country [38] 0 0
Croatia
State/province [38] 0 0
Slavonski Brod
Country [39] 0 0
Croatia
State/province [39] 0 0
Zagreb
Country [40] 0 0
Czech Republic
State/province [40] 0 0
Brno
Country [41] 0 0
Czech Republic
State/province [41] 0 0
Hradec Kralove
Country [42] 0 0
Czech Republic
State/province [42] 0 0
Liberec
Country [43] 0 0
Czech Republic
State/province [43] 0 0
Nova Ves pod Plesi
Country [44] 0 0
Czech Republic
State/province [44] 0 0
Olomouc
Country [45] 0 0
Czech Republic
State/province [45] 0 0
Pardubice
Country [46] 0 0
Czech Republic
State/province [46] 0 0
Prague
Country [47] 0 0
Czech Republic
State/province [47] 0 0
Praha 10
Country [48] 0 0
Czech Republic
State/province [48] 0 0
Praha 2
Country [49] 0 0
Czech Republic
State/province [49] 0 0
Pribram
Country [50] 0 0
Egypt
State/province [50] 0 0
Alexandria
Country [51] 0 0
Egypt
State/province [51] 0 0
Cairo
Country [52] 0 0
Guatemala
State/province [52] 0 0
Guatemala
Country [53] 0 0
India
State/province [53] 0 0
Andh Prad
Country [54] 0 0
India
State/province [54] 0 0
Delhi
Country [55] 0 0
India
State/province [55] 0 0
Karna
Country [56] 0 0
India
State/province [56] 0 0
Kerala
Country [57] 0 0
India
State/province [57] 0 0
Kilpauk
Country [58] 0 0
India
State/province [58] 0 0
Madh Prad
Country [59] 0 0
India
State/province [59] 0 0
Mahara
Country [60] 0 0
India
State/province [60] 0 0
Tamilnadu
Country [61] 0 0
India
State/province [61] 0 0
W Bengal
Country [62] 0 0
India
State/province [62] 0 0
Bangalore
Country [63] 0 0
India
State/province [63] 0 0
Chennai
Country [64] 0 0
India
State/province [64] 0 0
Hyderabad
Country [65] 0 0
India
State/province [65] 0 0
Kolkata
Country [66] 0 0
India
State/province [66] 0 0
Mumbai
Country [67] 0 0
India
State/province [67] 0 0
Pune
Country [68] 0 0
India
State/province [68] 0 0
West Bengal
Country [69] 0 0
Indonesia
State/province [69] 0 0
Jakarta
Country [70] 0 0
Indonesia
State/province [70] 0 0
Sumatera Utara
Country [71] 0 0
Indonesia
State/province [71] 0 0
West Java
Country [72] 0 0
Italy
State/province [72] 0 0
Aviano
Country [73] 0 0
Italy
State/province [73] 0 0
Bologna
Country [74] 0 0
Italy
State/province [74] 0 0
Brescia
Country [75] 0 0
Italy
State/province [75] 0 0
Cremona
Country [76] 0 0
Italy
State/province [76] 0 0
Lido di Camaiore
Country [77] 0 0
Italy
State/province [77] 0 0
Lucca
Country [78] 0 0
Italy
State/province [78] 0 0
Meldola
Country [79] 0 0
Italy
State/province [79] 0 0
Mirano
Country [80] 0 0
Italy
State/province [80] 0 0
Noale
Country [81] 0 0
Italy
State/province [81] 0 0
Potenza
Country [82] 0 0
Italy
State/province [82] 0 0
Rimini
Country [83] 0 0
Italy
State/province [83] 0 0
Udine
Country [84] 0 0
Korea, Republic of
State/province [84] 0 0
Seoul
Country [85] 0 0
Lebanon
State/province [85] 0 0
Beirut
Country [86] 0 0
Malta
State/province [86] 0 0
Floriana
Country [87] 0 0
Mexico
State/province [87] 0 0
Aguascelientes
Country [88] 0 0
New Zealand
State/province [88] 0 0
Christchurch
Country [89] 0 0
Philippines
State/province [89] 0 0
Cebu City
Country [90] 0 0
Philippines
State/province [90] 0 0
Pasig City
Country [91] 0 0
Poland
State/province [91] 0 0
Gdansk
Country [92] 0 0
Poland
State/province [92] 0 0
Krakow
Country [93] 0 0
Poland
State/province [93] 0 0
Olsztyn
Country [94] 0 0
Romania
State/province [94] 0 0
Baia Mare
Country [95] 0 0
Romania
State/province [95] 0 0
Cluj Napoca
Country [96] 0 0
Romania
State/province [96] 0 0
Suceava
Country [97] 0 0
Russian Federation
State/province [97] 0 0
Chelyabinsk
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Kursk
Country [99] 0 0
Russian Federation
State/province [99] 0 0
Moscow
Country [100] 0 0
Russian Federation
State/province [100] 0 0
Pyatigorsk
Country [101] 0 0
Russian Federation
State/province [101] 0 0
St. Petersburg
Country [102] 0 0
South Africa
State/province [102] 0 0
Cape Town
Country [103] 0 0
Spain
State/province [103] 0 0
Alcorcon
Country [104] 0 0
Spain
State/province [104] 0 0
Barcelona
Country [105] 0 0
Spain
State/province [105] 0 0
Elche
Country [106] 0 0
Spain
State/province [106] 0 0
Madrid
Country [107] 0 0
Spain
State/province [107] 0 0
Santander
Country [108] 0 0
Spain
State/province [108] 0 0
Sevilla
Country [109] 0 0
Taiwan
State/province [109] 0 0
Kaohsiung
Country [110] 0 0
Taiwan
State/province [110] 0 0
Taichung County
Country [111] 0 0
Taiwan
State/province [111] 0 0
Taipei
Country [112] 0 0
Thailand
State/province [112] 0 0
Bangkok
Country [113] 0 0
Thailand
State/province [113] 0 0
Chiang Mai
Country [114] 0 0
Thailand
State/province [114] 0 0
Rajathevee District
Country [115] 0 0
Turkey
State/province [115] 0 0
Adana
Country [116] 0 0
Turkey
State/province [116] 0 0
Gaziantep
Country [117] 0 0
Turkey
State/province [117] 0 0
Istanbul
Country [118] 0 0
Turkey
State/province [118] 0 0
Izmir
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Wirral
Country [120] 0 0
United Kingdom
State/province [120] 0 0
London
Country [121] 0 0
United Kingdom
State/province [121] 0 0
Sutton
Country [122] 0 0
United Kingdom
State/province [122] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Eli Lilly and Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to gather information about the use of an investigational drug
called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.
Trial website
https://clinicaltrials.gov/show/NCT00917384
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications